retatrutide latest clinical trial results Results: 24% Weight Loss in 48 Weeks Eli Lilly touts strong results

While safety within the phase 3 program is sufficient for marketing authorization (although the risk of cardiovascular events should not exceed a hazard ratio of 1.8 according to a guidance document that was released by the FDA at that time), it is the post-marketing phase in which rare adverse events and any other potential safety risks are identified or resolved

Cell Cycle 11 , 41074108 (2012)

Guitera, P

Legitimate prescription GLP-1 medications come from regulated manufacturers through licensed pharmacies

But what makes GLP-1 agonists so revolutionary

With creatine, my soreness went from ow, even typing hurts to a little tight, but totally manageable by the next morning